Page 243 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 243
Viral Hepatitis: Hepatitis C - Clinical (Except Therapy)
P0709 SURVIVAL OF PATIENTS INFECTED BY CHRONIC
HEPATITIS C AND F0F1 FIBROSIS AT BASELINE AFTER A 15
YEARS FOLLOW-UP
Caroline Jézéquel*, Edouard Bardou-Jacquet,Yoann Desille,
Isabelle Renard, Fabrice Lainé, Caroline Lelan, Marianne Latournerie,
Anne Guillygomarch, Pauline Houssel-Debry, Romain Moirand,
Yves Deugnier, Dominique Guyader, France
P0710 ROLE OF HEPATITIS C VIRUS (HCV) IN THE EARLY
ARTERIOSCLEROTIC PROCESS AND AUTONOMIC
DISFUNCTION
Luisa Cavalletto*, Franca Bilora, Lucia Sarolo, Maria T. Sartori,
Paolo Prandoni, Angelo Gatta, Liliana Chemello, Italy
P0711 GENOME-WIDE ASSOCIATION STUDY OF RESPONSE
TO SOFOSBUVIR-RIBAVIRIN TREATMENT IN GT2/3 HCV
PATIENTS ePOSTERS
Sarah E. Kleinstein*, Thomas J. Urban, Nanye Long,
Alexander Thompson, Edward J. Gane, Stefan Zeuzem,
Zhaoshi Jiang, Dongliang Ge, Matthew S. Paulson, Robert H. Hyland,
Diana M. Brainard, Anuj Gaggar, G. Mani Subramanian,
John G. McHutchison, Andrew Muir, Mark Sulkowski, Eric Lawitz,
David B. Goldstein, The United States
P0712 THE PHARMACOKINETICS OF GS-5816, A PANGENOTYPIC
HCV-SPECIFIC NS5A INHIBITOR, IN HCV-UNINFECTED
SUBJECTS WITH SEVERE RENAL IMPAIRMENT
Erik Mogalian*, Anita Mathias, Diana Brainard, Gong Shen,
John McNally, Karim Sajwani, Richard Robson, Daniel Ries,
Kenneth Lasseter, Thomas Marbury, The United States
P0713 THE IMPACT OF LEDIPASVIR (LDV)/SOFOSBUVIR (SOF)
COMBINATION ON HEALTH-RELATED QUALITY OF LIFE
(HRQL) AND PATIENT-REPORTED OUTCOMES (PROS) IN
CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C (CH-
C): THE SIRIUS STUDY
Zobair Younossi*, Maria Stepanova, Stanislas Pol, Jean-Pierre Bronowicki,
Patrizia Carrieri, Marc Bourlière, The United States
Vienna, Austria • April 22–26, 2015 243
P0709 SURVIVAL OF PATIENTS INFECTED BY CHRONIC
HEPATITIS C AND F0F1 FIBROSIS AT BASELINE AFTER A 15
YEARS FOLLOW-UP
Caroline Jézéquel*, Edouard Bardou-Jacquet,Yoann Desille,
Isabelle Renard, Fabrice Lainé, Caroline Lelan, Marianne Latournerie,
Anne Guillygomarch, Pauline Houssel-Debry, Romain Moirand,
Yves Deugnier, Dominique Guyader, France
P0710 ROLE OF HEPATITIS C VIRUS (HCV) IN THE EARLY
ARTERIOSCLEROTIC PROCESS AND AUTONOMIC
DISFUNCTION
Luisa Cavalletto*, Franca Bilora, Lucia Sarolo, Maria T. Sartori,
Paolo Prandoni, Angelo Gatta, Liliana Chemello, Italy
P0711 GENOME-WIDE ASSOCIATION STUDY OF RESPONSE
TO SOFOSBUVIR-RIBAVIRIN TREATMENT IN GT2/3 HCV
PATIENTS ePOSTERS
Sarah E. Kleinstein*, Thomas J. Urban, Nanye Long,
Alexander Thompson, Edward J. Gane, Stefan Zeuzem,
Zhaoshi Jiang, Dongliang Ge, Matthew S. Paulson, Robert H. Hyland,
Diana M. Brainard, Anuj Gaggar, G. Mani Subramanian,
John G. McHutchison, Andrew Muir, Mark Sulkowski, Eric Lawitz,
David B. Goldstein, The United States
P0712 THE PHARMACOKINETICS OF GS-5816, A PANGENOTYPIC
HCV-SPECIFIC NS5A INHIBITOR, IN HCV-UNINFECTED
SUBJECTS WITH SEVERE RENAL IMPAIRMENT
Erik Mogalian*, Anita Mathias, Diana Brainard, Gong Shen,
John McNally, Karim Sajwani, Richard Robson, Daniel Ries,
Kenneth Lasseter, Thomas Marbury, The United States
P0713 THE IMPACT OF LEDIPASVIR (LDV)/SOFOSBUVIR (SOF)
COMBINATION ON HEALTH-RELATED QUALITY OF LIFE
(HRQL) AND PATIENT-REPORTED OUTCOMES (PROS) IN
CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C (CH-
C): THE SIRIUS STUDY
Zobair Younossi*, Maria Stepanova, Stanislas Pol, Jean-Pierre Bronowicki,
Patrizia Carrieri, Marc Bourlière, The United States
Vienna, Austria • April 22–26, 2015 243
